Search Within

DYSKINESIAS

Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Journal: Current Drug Safety
Volume: 14, Issue: 1
Page: 21-26
Authors: Viswam Subeesh*, Eswaran Maheswari, Hemendra Singh, Thomas Elsa Beulah and Ann Mary Swaroop

Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug

Journal: Current Drug Safety
Volume: 14, Issue: 1
Page: 51-52
Authors: Dhruvkumar M. Patel, Jayanti K. Gurumukhani, Mukundkumar V. Patel* and Greshaben R. Patel

The Role of Phase Image in the Detection of Myocardial Dyskinesia by Magnetic Resonance Imaging (MRI)

Journal: Current Medical Imaging
Volume: 15, Issue: 2
Page: 214-219
Authors: Narjes Benameur*, Younes Arous, Nejmeddine ben Abdallah and Tarek Kraiem

Dopamine: Agonists and Neurodegenerative Disorders

Journal: Current Drug Targets
Volume: 19, Issue: 14
Page: 1599-1611
Authors: Saba Khanam and Yasir Hasan Siddique*

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease

Journal: Current Neuropharmacology
Volume: 16, Issue: 6
Page: 786-848
Authors: Agostinho Lemos, Rita Melo, Antonio Jose Preto, Jose Guilherme Almeida, Irina Sousa Moreira* and Maria Natalia Dias Soeiro Cordeiro*

New Trends in the Treatment of Schizophrenia

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 16, Issue: 8
Page: 900-906
Authors: Herbert Y. Meltzer*

Monoamine Oxidase B Inhibitors in Parkinson's Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 16, Issue: 4
Page: 425-439
Authors: Livia Dezsi and Laszlo Vecsei*

Recent Advances on Nitric Oxide in the Upper Airways

Journal: Current Medicinal Chemistry
Volume: 23, Issue: 24
Page: 2736-2745
Authors: Mauro Maniscalco, Andrea Bianco, Gennaro Mazzarella and Andrea Motta

mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias

Journal: Current Neuropharmacology
Volume: 14, Issue: 5
Page: 481-493
Authors: Nicolas Morin, Marc Morissette, Laurent Grégoire and Thérèse Di Paolo

Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System

Journal: Current Medicinal Chemistry
Volume: 23, Issue: 9
Page: 874-883
Authors: Zsófia Majláth, József Toldi, Ferenc Fülöp and László Vécsei

Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series

Journal: Current Drug Safety
Volume: 11, Issue: 1
Page: 102-103
Authors: Suravi Patra

Poor Prognostic Outcome in Cerebral Venous Sinus Thrombosis Associated with Dyskinesia and Elevated Platelet Volume

Journal: Current Neurovascular Research
Volume: 13, Issue: 1
Page: 50-57
Authors: Shousen Wang, Bingyang Xu, Qingshuang Zhao, Jun Li, Jingfang Hong, Liangfeng Wei and Lin Zhao

Antidepressant Related Movement Disorders in the Elderly

Journal: Current Psychiatry Reviews
Volume: 11, Issue: 2
Page: 116-123
Authors: Rajesh R. Tampi, Lydia Shook and Deena J. Tampi

Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center

Journal: Current Psychopharmacology
Volume: 3, Issue: 1
Page: 79-85
Authors: Rony Sabbag, Bitya Fridman and Uriel Heresco-Levy

A Genetic Dissection of Antipsychotic Induced Movement Disorders

Journal: Current Medicinal Chemistry
Volume: 20, Issue: 3
Page: 312-330
Authors: C. Crisafulli, A. Drago, A. Sidoti and A. Serretti

Neurobiological Basis of Dyskinetic Effects Induced by Antipsychotics: the Contribution of Animal Models

Journal: Current Medicinal Chemistry
Volume: 20, Issue: 3
Page: 389-396
Authors: Meaghan C. Creed and Jose N. Nobrega


Signal Pathways Mediating Antidepressant and Antipsychotic Drugs on Neuronal Cell Survival

Journal: Current Medicinal Chemistry - Central Nervous System Agents
Volume: 4, Issue: 2
Page: 105-118
Authors: Anke Post, Osborne F.X. Almeida and Florian Holsboer

Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10, Issue: 7
Page: 777-791
Authors: Massimo Pierucci, Salvatore Galati, Mario Valentino, Vincenzo Di Matteo, Arcangelo Benigno, Alessandro Pitruzzella, Richard Muscat and Giuseppe Di Giovanni

The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 5, Issue: 1
Page: 25-43
Authors: L. Leriche, E. Bezard, C. Gross, O. Guillin, B. L. Foll, J. Diaz and P. Sokoloff

The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies

Journal: Current Medicinal Chemistry
Volume: 11, Issue: 3
Page: 389-396
Authors: Paul L. Chazot

L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment

Journal: Current Pharmaceutical Design
Volume: 17, Issue: 32
Page: 3482-3493
Authors: Antonio Di Stefano, Piera Sozio, Laura Serafina Cerasa and Antonio Iannitelli

Current Status of Antipsychotic Treatment

Journal: Current Drug Targets - CNS & Neurological Disorders
Volume: 1, Issue: 2
Page: 123-128
Authors: Robert R. Conley and Deanna L. Kelly

Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor

Journal: Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
Volume: 9, Issue: 2
Page: 94-101
Authors: Michel C.F. Shamy, Clement Zai, Vincenzo S. Basile, James L. Kennedy, Daniel J. Muller and Mario Masellis

A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia

Journal: Current Drug Targets
Volume: 7, Issue: 9
Page: 1225-1229
Authors: U. Taksh

The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms

Journal: Current Pharmaceutical Design
Volume: 10, Issue: 18
Page: 2239-2248
Authors: K. Burgyone, K. Aduri, J. Ananth and S. Parameswaran

The Evolution of Pharmacological Treatment for Parkinsons Disease

Journal: Recent Patents on CNS Drug Discovery (Discontinued)
Volume: 3, Issue: 1
Page: 50-54
Authors: Quincy J. Almeida and H. Christopher Hyson

Therapeutic Strategies in Parkinsons Disease

Journal: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization)
Volume: 2, Issue: 2
Page: 135-147
Authors: Muchukunte M.S. Bharath

Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics

Journal: Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
Volume: 9, Issue: 4
Page: 323-331
Authors: Eugene Lin and Shih-Jen Tsai

An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments

Journal: Current Medicinal Chemistry
Volume: 13, Issue: 30
Page: 3705-3718
Authors: Isabel Lastres-Becker and Javier Fernandez-Ruiz

Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications

Journal: Current Medicinal Chemistry
Volume: 14, Issue: 28
Page: 2996-3002
Authors: Jiao Mo, Yang Guo, Yu-She Yang, Jing-Shan Shen, Guo-Zhang Jin and Xuechu Zhen

Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists

Journal: Current Topics in Medicinal Chemistry
Volume: 8, Issue: 12
Page: 1049-1067
Authors: Trond Kvernmo, John Houben and Ingebrigt Sylte

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 8, Issue: 6
Page: 475-491
Authors: Kari A. Johnson, P. Jeffrey Conn and Colleen M. Niswender

The Rabbit Syndrome: State of the Art

Journal: Current Clinical Pharmacology
Volume: 2, Issue: 3
Page: 212-216
Authors: Mario Catena, Andrea Fagiolini, Giorgio Consoli, Francesca Ducci, Michela Picchetti and Donatella Marazziti

Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders

Journal: Current Drug Therapy
Volume: 6, Issue: 1
Page: 17-34
Authors: Aravind Mittur

Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review

Journal: Central Nervous System Agents in Medicinal Chemistry
Volume: 8, Issue: 4
Page: 249-256
Authors: Oswald J.N. Bloemen, M. B. de Koning, E. Boot, J. Booij and T.A. M.J. van Amelsvoort

Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 9, Issue: 5
Page: 596-600
Authors: Sergi Ferre, Carmen Lluis, Jose Luis Lanciego and Rafael Franco

Tardive Dyskinesia with Atypical Antipsychotic Drugs

Journal: Current Drug Therapy
Volume: 2, Issue: 3
Page: 168-176
Authors: Jambur Ananth, Kartik Ananth and Aparna Keshavan

Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment

Journal: Current Pharmaceutical Design
Volume: 17, Issue: 5
Page: 471-488
Authors: Elaine Del-Bel, Fernando Eduardo Padovan-Neto, Rita Raisman-Vozari and Marcio Lazzarini

Etiopathogenesis and Treatment of Parkinsons Disease

Journal: Current Topics in Medicinal Chemistry
Volume: 9, Issue: 10
Page: 860-868
Authors: David A. Gallagher and Anthony H. V. Schapira

Targeting Nicotinic Receptors for Parkinson's Disease Therapy

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10, Issue: 6
Page: 651-658
Authors: Maryka Quik, Tanuja Bordia, Luping Huang and Xiomara Perez

Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics

Journal: Current Medicinal Chemistry
Volume: 14, Issue: 22
Page: 2330-2334
Authors: Francesco Fornai, Adolfo Bandettini di Poggio, Antonio Pellegrini, Stefano Ruggieri and Antonio Paparelli

The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease

Journal: Current Pharmaceutical Design
Volume: 17, Issue: 5
Page: 489-507
Authors: Rui D. S. Prediger, Aderbal S. Aguiar, Eduardo L. G. Moreira, Filipe C. Matheus, Adalberto A. Castro, Roger Walz, Andreza F. De Bem, Alexandra Latini, Carla I. Tasca, Marcelo Farina and Rita Raisman-Vozari

Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders

Journal: Current Psychiatry Reviews
Volume: 5, Issue: 4
Page: 271-275
Authors: Tsuyoshi Miyaoka and Jun Horiguchi

Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10, Issue: 6
Page: 670-684
Authors: M. A. Cenci, K. E. Ohlin and P. Odin

Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist

Journal: Current Pharmaceutical Design
Volume: 11, Issue: 23
Page: 3051-3060
Authors: E. Selimoglu

Oxidative Stress in Schizophrenia

Journal: Current Neuropharmacology
Volume: 9, Issue: 2
Page: 301-312
Authors: Iztok Grabnar, Tomas Vovk, Blanka Kores Plesnicar and Marija Boskovic

New Insight into the Therapeutic Role of 5-HT1A Receptors in Central Nervous System Disorders

Journal: Central Nervous System Agents in Medicinal Chemistry
Volume: 10, Issue: 2
Page: 148-157
Authors: Yukihiro Ohno

The Surgical Management of Parkinson's Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10, Issue: 6
Page: 685-692
Authors: Francisco A. Ponce and Andres M. Lozano

Pharmacogenomic-Guided Rational Therapeutic Drug Monitoring: Conceptual Framework and Application Platforms for Atypical Antipsychotics

Journal: Current Medicinal Chemistry
Volume: 11, Issue: 3
Page: 297-312
Authors: Lawrence J. Albers and Vural Ozdemir

Clozapine Safety, 35 Years Later

Journal: Current Drug Safety
Volume: 6, Issue: 3
Page: 164-184
Authors: Michele Raja

A Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment

Journal: Medicinal Chemistry Reviews - Online (Discontinued)
Volume: 2, Issue: 3
Page: 177-182
Authors: Robert R. Conley and Deanna L. Kelly